Enfusion (ENFN) shows great potential for growth with its SaaS solution for investment managers, bolstered by a healthy industry. Read an analysis here.

Enfusion shows promise with 21% medium-term growth targets, positive free cash flow, GAAP profitability, and no debt, benefiting from falling interest rates. Despite no significant economic moat ...

Enfusion shareholders are down 55% for the year, even worse than the market loss of 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped.

The projected fair value for Enfusion is US$15.31 based on 2 Stage Free Cash Flow to Equity Current share price of US$9.94 suggests Enfusion is potentially 35% undervalued The US$9.61 analyst ...

Additionally, Enfusion increased its full-year revenue by 40% compared to 2020, to $111.7 million. Enfusion CEO Thomas Kim said in a press release that the company "finished the year on a strong ...

CHICAGO, Sept. 20, 2018 /PRNewswire/ -- Enfusion, a leading provider of innovative, cloud-based investment management software and outsourced midd ...

Enfusion, which provides cloud-based portfolio management and risk systems to investment funds, is valued at roughly $1 billion. Since going public in 2021, Enfusion's shares have lost more than ...

Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one cloud-native system.

ENFUSION AT A GLANCE. FOUNDED: 1997 EMPLOYEES: Globally, 153; locally, 77. WHAT THEY DO: Enfusion creates investment management software and outsourced services to brokerages. WHERE THEY DO IT: ...